Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors
Introduction: Phosphodiesterase type 5 inhibitors (PDE5Is) are the first-line drugs in the
management of erectile dysfunction (ED). However, over the past two decades tremendous …
management of erectile dysfunction (ED). However, over the past two decades tremendous …
[HTML][HTML] Phosphodiesterase type 5 inhibitors as a treatment for erectile dysfunction: Current information and new horizons
JE Ferguson III, CC Carson III - Arab Journal of Urology, 2013 - Elsevier
Introduction Over the past 15 years, the discovery and development of oral medications that
selectively inhibit the enzyme phosphodiesterase type 5 (PDE5) have revolutionised the …
selectively inhibit the enzyme phosphodiesterase type 5 (PDE5) have revolutionised the …
[HTML][HTML] Advancements in phosphodiesterase 5 inhibitors: unveiling present and future perspectives
Phosphodiesterase 5 (PDE5) inhibitors presented themselves as important players in the
nitric oxide/cGMP pathway, thus exerting a profound impact on various physiological and …
nitric oxide/cGMP pathway, thus exerting a profound impact on various physiological and …
Therapy of ED: PDE-5 inhibitors
R Shabsigh - Endocrine, 2004 - Springer
The development of phosphodiesterase inhibitors, which are selective for the type 5
isoenzyme, has revolutionized the initial evaluation and treatment of men with erectile …
isoenzyme, has revolutionized the initial evaluation and treatment of men with erectile …
Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors
CC Carson III - The American journal of cardiology, 2005 - Elsevier
Phosphodiesterase type 5 (PDE5) inhibitors have revolutionized the treatment of erectile
dysfunction (ED). Those safe and effective agents were originally developed for their …
dysfunction (ED). Those safe and effective agents were originally developed for their …
Novel PDE5 inhibitors for the treatment of male erectile dysfunction
JS Kalsi, G Bahadur, A Muneer, O Ozturk… - Reproductive …, 2003 - Elsevier
Erectile dysfunction (ED) affects the lives of approximately 150 million men worldwide. ED
may be a cause of male sub-fertility in a significant proportion of patients. There is now an …
may be a cause of male sub-fertility in a significant proportion of patients. There is now an …
[HTML][HTML] The effect of phosphodiesterase-type 5 inhibitors on erectile function: an overview of systematic reviews
N Pyrgidis, I Mykoniatis, AB Haidich, M Tirta… - Frontiers in …, 2021 - frontiersin.org
Background: Multiple systematic reviews explore the effect of phosphodiesterase type 5
(PDE5) inhibitors on erectile dysfunction (ED), with each study addressing specific …
(PDE5) inhibitors on erectile dysfunction (ED), with each study addressing specific …
Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease
N Tzoumas, TE Farrah, N Dhaun… - British Journal of …, 2020 - Wiley Online Library
PDE type 5 inhibitors (PDE5Is), such as sildenafil, tadalafil and vardenafil, are a class of
drugs used to prolong the physiological effects of NO/cGMP signalling in tissues through the …
drugs used to prolong the physiological effects of NO/cGMP signalling in tissues through the …
Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract
ABSTRACT Introduction Phosphodiesterase type 5 (PDE5) inhibitors ameliorate low urinary
tract (LUT) symptoms in men with ED and symptomatic benign prostatic hyperplasia (BPH) …
tract (LUT) symptoms in men with ED and symptomatic benign prostatic hyperplasia (BPH) …
PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer
Abstract The phosphodiesterase 5 (PDE5) inhibitors, including sildenafil (Viagra™),
vardenafil (Levitra™), and tadalafil (Cialis™) have been developed for treatment of erectile …
vardenafil (Levitra™), and tadalafil (Cialis™) have been developed for treatment of erectile …